Literature DB >> 2427196

Phase II study of fludarabine phosphate for the treatment of advanced non-small cell carcinoma of the lung: a Southwest Oncology Group Study.

G R Weiss, J Crowley, D D Von Hoff, S A Taylor, R J Belt, C A Coltman, H E Hynes, J J Costanzi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2427196

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


× No keyword cloud information.
  4 in total

Review 1.  Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy.

Authors:  S R Ross; D McTavish; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

2.  Ocular toxicity of fludarabine: a purine analog.

Authors:  Xiaoyan Ding; Alexandra A Herzlich; Rachel Bishop; Jingsheng Tuo; Chi-Chao Chan
Journal:  Expert Rev Ophthalmol       Date:  2008-02

3.  Phase II study of fludarabine phosphate in patients with advanced colorectal carcinoma.

Authors:  J A Ajani; J L Abbruzzese; J S Faintuch; R Blackburn; B Levin; B M Boman
Journal:  Invest New Drugs       Date:  1988-04       Impact factor: 3.850

Review 4.  Fludarabine phosphate. A new anticancer drug with significant activity in patients with chronic lymphocytic leukemia and in patients with lymphoma.

Authors:  G Rodriguez
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.